Literature DB >> 27783945

The SIRT2 Deacetylase Stabilizes Slug to Control Malignancy of Basal-like Breast Cancer.

Wenhui Zhou1, Thomas K Ni1, Ania Wronski1, Benjamin Glass2, Adam Skibinski1, Andrew Beck2, Charlotte Kuperwasser3.   

Abstract

Overabundance of Slug protein is common in human cancer and represents an important determinant underlying the aggressiveness of basal-like breast cancer (BLBC). Despite its importance, this transcription factor is rarely mutated in BLBC, and the mechanism of its deregulation in cancer remains unknown. Here, we report that Slug undergoes acetylation-dependent protein degradation and identify the deacetylase SIRT2 as a key mediator of this post-translational mechanism. SIRT2 inhibition rapidly destabilizes Slug, whereas SIRT2 overexpression extends Slug stability. We show that SIRT2 deacetylates Slug protein at lysine residue K116 to prevent Slug degradation. Interestingly, SIRT2 is frequently amplified and highly expressed in BLBC. Genetic depletion and pharmacological inactivation of SIRT2 in BLBC cells reverse Slug stabilization, cause the loss of clinically relevant pathological features of BLBC, and inhibit tumor growth. Our results suggest that targeting SIRT2 may be a rational strategy for diminishing Slug abundance and its associated malignant traits in BLBC.
Copyright © 2016 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  SIRT2; Slug; acetylation; basal-like breast cancer; deacetylase; protein stability; sirtinol; triple-negative breast cancer

Mesh:

Substances:

Year:  2016        PMID: 27783945      PMCID: PMC5108094          DOI: 10.1016/j.celrep.2016.10.006

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  64 in total

Review 1.  Triple-negative breast cancer.

Authors:  William D Foulkes; Ian E Smith; Jorge S Reis-Filho
Journal:  N Engl J Med       Date:  2010-11-11       Impact factor: 91.245

2.  Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties.

Authors:  Dario Ponti; Aurora Costa; Nadia Zaffaroni; Graziella Pratesi; Giovanna Petrangolini; Danila Coradini; Silvana Pilotti; Marco A Pierotti; Maria Grazia Daidone
Journal:  Cancer Res       Date:  2005-07-01       Impact factor: 12.701

Review 3.  Dissecting the heterogeneity of triple-negative breast cancer.

Authors:  Otto Metzger-Filho; Andrew Tutt; Evandro de Azambuja; Kamal S Saini; Giuseppe Viale; Sherene Loi; Ian Bradbury; Judith M Bliss; Hatem A Azim; Paul Ellis; Angelo Di Leo; José Baselga; Christos Sotiriou; Martine Piccart-Gebhart
Journal:  J Clin Oncol       Date:  2012-03-26       Impact factor: 44.544

4.  GSK3β controls epithelial-mesenchymal transition and tumor metastasis by CHIP-mediated degradation of Slug.

Authors:  S-H Kao; W-L Wang; C-Y Chen; Y-L Chang; Y-Y Wu; Y-T Wang; S-P Wang; A I Nesvizhskii; Y-J Chen; T-M Hong; P-C Yang
Journal:  Oncogene       Date:  2013-07-15       Impact factor: 9.867

5.  Canonical Wnt signaling regulates Slug activity and links epithelial-mesenchymal transition with epigenetic Breast Cancer 1, Early Onset (BRCA1) repression.

Authors:  Zhao-Qiu Wu; Xiao-Yan Li; Casey Yuexian Hu; Michael Ford; Celina G Kleer; Stephen J Weiss
Journal:  Proc Natl Acad Sci U S A       Date:  2012-09-24       Impact factor: 11.205

6.  Expression/localization patterns of sirtuins (SIRT1, SIRT2, and SIRT7) during progression of cervical cancer and effects of sirtuin inhibitors on growth of cervical cancer cells.

Authors:  Sapna Singh; P Uday Kumar; Suresh Thakur; Shashi Kiran; Bijoya Sen; Shreya Sharma; Vishnu Vardhan Rao; A R Poongothai; Gayatri Ramakrishna
Journal:  Tumour Biol       Date:  2015-03-21

7.  Acetylation regulates gluconeogenesis by promoting PEPCK1 degradation via recruiting the UBR5 ubiquitin ligase.

Authors:  Wenqing Jiang; Shiwen Wang; Mengtao Xiao; Yan Lin; Lisha Zhou; Qunying Lei; Yue Xiong; Kun-Liang Guan; Shimin Zhao
Journal:  Mol Cell       Date:  2011-07-08       Impact factor: 17.970

8.  A SIRT2-Selective Inhibitor Promotes c-Myc Oncoprotein Degradation and Exhibits Broad Anticancer Activity.

Authors:  Hui Jing; Jing Hu; Bin He; Yashira L Negrón Abril; Jack Stupinski; Keren Weiser; Marisa Carbonaro; Ying-Ling Chiang; Teresa Southard; Paraskevi Giannakakou; Robert S Weiss; Hening Lin
Journal:  Cancer Cell       Date:  2016-03-14       Impact factor: 31.743

9.  Identification of a small molecule SIRT2 inhibitor with selective tumor cytotoxicity.

Authors:  Yingjia Zhang; Qingyan Au; Menghua Zhang; Jack R Barber; Shi Chung Ng; Bin Zhang
Journal:  Biochem Biophys Res Commun       Date:  2009-06-25       Impact factor: 3.575

10.  Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial.

Authors:  Jack Cuzick; Ivana Sestak; Michael Baum; Aman Buzdar; Anthony Howell; Mitch Dowsett; John F Forbes
Journal:  Lancet Oncol       Date:  2010-11-17       Impact factor: 41.316

View more
  31 in total

1.  SIRT2-mediated inactivation of p73 is required for glioblastoma tumorigenicity.

Authors:  Kosuke Funato; Tomoatsu Hayashi; Kanae Echizen; Lumi Negishi; Naomi Shimizu; Ryo Koyama-Nasu; Yukiko Nasu-Nishimura; Yasuyuki Morishita; Viviane Tabar; Tomoki Todo; Yasushi Ino; Akitake Mukasa; Nobuhito Saito; Tetsu Akiyama
Journal:  EMBO Rep       Date:  2018-09-13       Impact factor: 8.807

2.  Quantitative Analysis of NAD Synthesis-Breakdown Fluxes.

Authors:  Ling Liu; Xiaoyang Su; William J Quinn; Sheng Hui; Kristin Krukenberg; David W Frederick; Philip Redpath; Le Zhan; Karthikeyani Chellappa; Eileen White; Marie Migaud; Timothy J Mitchison; Joseph A Baur; Joshua D Rabinowitz
Journal:  Cell Metab       Date:  2018-05-01       Impact factor: 27.287

Review 3.  Phenotypic Plasticity: Driver of Cancer Initiation, Progression, and Therapy Resistance.

Authors:  Piyush B Gupta; Ievgenia Pastushenko; Adam Skibinski; Cedric Blanpain; Charlotte Kuperwasser
Journal:  Cell Stem Cell       Date:  2018-12-13       Impact factor: 24.633

4.  Identification of a novel small molecule that inhibits deacetylase but not defatty-acylase reaction catalysed by SIRT2.

Authors:  Norio Kudo; Akihiro Ito; Mayumi Arata; Akiko Nakata; Minoru Yoshida
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2018-06-05       Impact factor: 6.237

5.  Novel Lysine-Based Thioureas as Mechanism-Based Inhibitors of Sirtuin 2 (SIRT2) with Anticancer Activity in a Colorectal Cancer Murine Model.

Authors:  Ali Sohail Farooqi; Jun Young Hong; Ji Cao; Xuan Lu; Ian Robert Price; Qingjie Zhao; Tatsiana Kosciuk; Min Yang; Jessica Jingyi Bai; Hening Lin
Journal:  J Med Chem       Date:  2019-04-15       Impact factor: 7.446

Review 6.  Updates on the epigenetic roles of sirtuins.

Authors:  Tatsiana Kosciuk; Miao Wang; Jun Young Hong; Hening Lin
Journal:  Curr Opin Chem Biol       Date:  2019-03-12       Impact factor: 8.822

7.  The sirtuin family in cancer.

Authors:  Luis Filipe Costa-Machado; Pablo J Fernandez-Marcos
Journal:  Cell Cycle       Date:  2019-07-25       Impact factor: 4.534

Review 8.  Naturally occurring small molecule compounds that target histone deacetylases and their potential applications in cancer therapy.

Authors:  Yuki Maemoto; Yuki Shimizu; Ryu Katoh; Akihiro Ito
Journal:  J Antibiot (Tokyo)       Date:  2021-08-23       Impact factor: 2.649

9.  A Glycoconjugated SIRT2 Inhibitor with Aqueous Solubility Allows Structure-Based Design of SIRT2 Inhibitors.

Authors:  Jun Young Hong; Ian Robert Price; Jessica Jingyi Bai; Hening Lin
Journal:  ACS Chem Biol       Date:  2019-08-02       Impact factor: 5.100

10.  CBP-mediated Slug acetylation stabilizes Slug and promotes EMT and migration of breast cancer cells.

Authors:  Xiaoyan Dai; Yanli Xin; Weizhi Xu; Xinxia Tian; Xiaofan Wei; Hongquan Zhang
Journal:  Sci China Life Sci       Date:  2020-07-29       Impact factor: 6.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.